Proteasome inhibition is an effective treatment for multiple myeloma (MM); however, targeting different components of the ubiquitin-proteasome system (UPS) remains elusive. Our RNA-interference studies identified proteasome-associated ubiquitin-receptor Rpn13 as a mediator of MM cell growth and survival. Here, we developed the first degrader of Rpn13, WL40, using a small-molecule-induced targeted protein degradation strategy to selectively degrade this component of the UPS. WL40 was synthesized by linking the Rpn13 covalent inhibitor RA190 with the cereblon (CRBN) binding ligand thalidomide. We show that WL40 binds to both Rpn13 and CRBN and triggers degradation of cellular Rpn13, and is therefore first-in-class in exploiting a covalent inhibitor for the development of degraders. Biochemical and cellular studies show that WL40-induced Rpn13 degradation is both CRBN E3 ligase-and Rpn13-dependent. Importantly, WL40 decreases viability in MM cell lines and patient MM cells, even those resistant to bortezomib. Mechanistically, WL40 interrupts Rpn13 function and activates caspase apoptotic cascade, ER stress response and p53/p21 signaling. In animal model studies, WL40 inhibits xenografted human MM cell growth and prolongs survival. Overall, our data show the development of the first UbR Rpn13 degrader with potent anti-MM activity, and provide proof of principle for the development of degraders targeting components of the UPS for therapeutic application.
Introduction
Multiple myeloma (MM) accounts for 10% of all hematologic malignancies and affects 30,200 new individuals annually in the United States, highlighting the need for development of novel therapeutic approaches. Proteasome inhibitors (PIs), such as bortezomib, carfilzomib, and ixazomib are FDA-approved drugs used for the treatment of relapsed/refractory and newly diagnosed MM [1] [2] [3] [4] . Although PI therapies have contributed to major advances, their clinical use has been associated with adverse effects and the emergence of drug resistance, underlying relapse of disease [2] [3] [4] [5] . Importantly, the ability of PIs to overcome resistance to conventional therapies has validated the ubiquitin-proteasome system (UPS) as a therapeutic target in MM. Other than the 20S proteasome holoenzyme, which is targeted by PIs [6] [7] [8] [9] , there are several other potential therapeutic targets within the UPS including deubiquitinating enzymes or ubiquitin receptors (UbRs), which represent targets to enhance or even overcome PI resistance.
Our and other studies have focused on validating and targeting the UbR Rpn13/ADRM1 upstream of the 20S proteasome in cancers and in MM in particular [10] [11] [12] [13] [14] . Rpn13 is associated with the 19S regulatory component of the proteasome and plays a key role in directing ubiquitinated substrates for degradation via the 20S proteasome [15] [16] [17] . Specifically, Rpn13 captures the ubiquitinated proteins as substrate, followed by removal of ubiquitin moieties from the substrate by deubiquitinating enzymes UCH37 at the 19S proteasome; the target protein is then unfolded by the AAA-ATPases for 20S proteasomemediated degradation. To date, strategies to delineate the functionality of Rpn13 used genetic modulation and smallmolecule inhibitors [10, 12, 14, 18, 19] . For example, we showed that Rpn13 expression level is higher in MM cells than in normal plasma cells and that Rpn13 mediates MM cell growth and survival [10] ; both RNA interference and a proof-of-concept Rpn13 inhibitor RA190 [11] confirmed that inhibiting Rpn13 induces MM cell growth inhibition [10] . Another study used a peptoid Rpn13 inhibitor to show antitumor responses [13] . However, currently there are no clinical grade agents targeting Rpn13.
Small-molecule inhibitors have shown clinical efficacy in many cancers, but their utility may be limited since (1) high systemic concentrations are required to inhibit diseaserelated target proteins to achieve clinical benefits, which triggers off-target binding activities; (2) inhibitors usually block the activity of one domain of multidomain proteins, leaving the functional properties of other domains intact. For example, Rpn13 inhibitor RA190 covalently reacts with cysteine residue 88 (Cys88) of Rpn13 Pru domain, but its interaction with the DEUBAD domain of Rpn13 is more labile due to the lack of a favorable binding pocket [11, 20, 21] ; and (3) inhibition of target proteins may trigger compensatory feedback mechanisms including protein overexpression/accumulation, resulting in inadequate inhibition of the protein [22, 23] . Inspired by the recent strategy utilizing small molecules to induce targeted protein degradation, we explored this alternative strategy by designing a small-molecule-based degrader to eliminate Rpn13 at the protein level. With both the inhibitor and degrader, we evaluated if protein degradation may overcome these limitations of small-molecule inhibitors.
Recent medicinal chemistry-based research led to the discovery of a mechanism-based chemical strategy for endogenous target protein degradation by using heterobifunctional small-molecule ligands to recruit E3 ubiquitin ligases to induce target protein degradation [22] [23] [24] [25] [26] [27] [28] . Degronimids, also known as proteolysis-targeting chimeras, are designed by conjugating the small-molecule binder of the target protein to an E3 ubiquitin ligase binding scaffold, such as the analogs of thalidomide for cereblon (CRBN) or ligands that bind to von Hippel-Lindau. Mechanistically, the degraders engage the target protein and recruit it to the E3 ubiquitin ligase, thereby promoting its ubiquitination and subsequent degradation by the proteasome [29] . This strategy has been applied to several proteins including the bromodomain and extra terminal family (BRD2, BRD3, and BRD4), BCR-ABL, FKBP12, ERRα, and RIPK2 [25, [29] [30] [31] .
In the current study, we designed a small-molecule inducer of Rpn13 degradation, WL40, by linking the Rpn13 inhibitor, RA190, to an immunomodulatory drug (IMiD) (thalidomide) as a ligand for CRBN E3 ligase. WL40 promotes ligand-induced degradation of Rpn13 by the proteasome, which is the first of its kind to utilize a covalent inhibitor as the targeted protein binder. Using both in vitro and in vivo preclinical models and MM patient cells, we further confirmed that WL40 triggers potent anti-MM activity, overcoming PI resistance. Collectively, our results show the promising anti-MM activity of the first Rpn13 degrader, WL40, and provide the scaffold for the development of degraders targeting components of the UPS for therapeutic application.
Materials and methods

Chemical synthesis of WL40
Detailed synthesis and characterization of all compounds are provided in Supplemental Information. All the chemical reagents were purchased from Sigma-Aldrich with proper quality control. The compound WL40 is fully characterized using 1 HNMR, 13 CNMR, and MS, based on the American Chemical Society guidelines. RA190 and WL40 were synthesized in the Qi laboratory and were fully characterized using 1 HNMR, 13 CNMR, and MS, based on the American Chemical Society guidelines.
Biochemical assay conditions
The biochemical assays for both CRBN binding and RPN13 binding were performed with minimal modifications from the manufacturer's protocol (PerkinElmer, USA). The assay details are described in Supplemental Information.
Cell culture and reagents
Human MM cell lines MM.1S, MM.1R, RPMI-8226, ANBL6.WT, ANBL6.BR, DOX40, INA6, and normal PBMCs were cultured in RPMI1640 complete medium. Informed consent was obtained from all patients in accordance with the Helsinki protocol. MM CD138-positive cells, bone marrow stromal cells (BMSCs), and plasmacytoid dendritic cells (pDCs) from MM patients were isolated and cultured as described previously [32] .
Immunoblotting
Cellular protein extracts were prepared using RIPA lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS). Protein lysates were subjected to immunoblotting using antibodies against poly ADP ribose polymerase (PARP, BD Bioscience Pharmingen, San Diego, CA), caspase-3, caspase-8, p53 (Santa Cruz Biotechnology), caspase-9, peIF2α (Abcam, Cambridge, MA), caspase-7, cyclin-B1, CDC25C, CDC2, p21, Rpn13, PERK, BIP, Calnexin, GFP, LC3A/B, α-tubulin (Cell Signaling, Beverly, MA), polyubiquitin (Enzo Life Sciences, Inc., Farmingdale, NY), or β-actin (Sigma-Aldrich, St. Louis, MO).
Proteasome activity assays
MM.1S cells were treated with WL40 (1 or 10 µM) or Bortezomib (1 µM) for 3 h; cells were then harvested and lysed in lysis buffer, followed by removal of debris by centrifugation. Total protein (25 µg) was analyzed for proteasome activity using the 20S proteasome Assay Kit (Calbiochem), as previously described [33] .
Cell viability and apoptosis analysis
Cell viability was determined by WST-1/CellTiter-Glo Luminescent assays, as described previously [34] . Apoptosis was measured using Annexin/PI staining [33] . The caspase activity assay and cell cycle analysis were performed as described previously [35] .
Generation of CRISPR/Cas9-knockout cell lines
We performed CRISPR/Cas9 genome editing to generate Rpn13-knockout (Rpn13-KO) HCT116 and MM.1S cell lines. Cells were transfected with Rpn13-CRISPR/Cas9-knockout (KO) plasmid (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) or the cell line Nucleofector Kit V (Amaxa Biosystems, Cologne, Germany), respectively. After 48 h incubation, green fluorescent protein (GFP)-positive cells were sorted. Rpn13-KO was confirmed by both protein expression studies and DNA sequencing.
Human MM xenograft model
Animal model studies were performed as described previously [32, 33, 36] . Briefly, CB17 SCID mice were subcutaneously inoculated with 5.0 × 10 6 MM. 1S cells. When tumors were measurable (100 mm 3 ) at~3 weeks after MMcell injection, mice (10 mice/group) were treated on a twiceweekly schedule with vehicle alone, WL40, or RA190. Mice were euthanized when tumor volume reached institutional limit (2000 mm   3 ). All animal experiment protocols were approved by and conformed to the relevant regulatory standards of the Institutional Animal Care and Use Committee at the Dana-Farber Cancer Institute.
Analysis of mice tumors
Tumors were harvested from WL40-treated and control animals. Tumor sections were fixed and paraffin-embedded for immunostaining to detect growth inhibition (Ki67), apoptosis (cleaved caspase-3), polyubiquitination (PolyU), and angiogenesis (CD31), as described previously [32, 34] . Tumor protein lysates from control vehicle-and WL40-treated mice were analyzed for caspase-8, poly-ubiquitin, or β-actin level using immunoblot analyses.
Statistical analysis
Statistical significance was derived using the two-tailed Student's t-test. Survival of mice was analyzed by GraphPad Prism software.
Results and discussion
Development of Rpn13 degrader
The main principle underlying the synthetic design of degraders is that bivalent molecules can interact with targeted proteins and E3 ligases simultaneously to induce the ubiquitination of targeted proteins. Therefore, we enlisted a small-molecule Rpn13 inhibitor, RA190, that covalently binds to Cys88 of the Rpn13 Pru domain. The covalent binding of RA190 to Rpn13 interrupts the recognition of polyubiquitinylated proteins that signals for subsequent degradation by the proteasome. Our degradation strategy utilized the E3 ligase, CRBN, and its binding molecules, IMiDs, one of which is thalidomide. These IMiDs bind to the E3 ubiquitin ligase complex (CUL4-RBX-DDB1 CRBN/CRL4 CRBN ) and have also been used in the treatment of MM. More specifically, we linked RA190 with thalidomide via either an alkyl linker or a polyethylene glycol (PEG) linker to create a set of potential degraders. Amongst these compounds, WL40, created by linking RA190 to thalidomide with a short PEG linker, showed promising activity (Fig. 1a) as a potent degrader [37] .
Specificity and functionality of WL40
We performed several experiments to confirm the specificity of WL40. Firstly, we assessed WL40-CRBN binding activity using in vitro AlphaScreen assays, as previously described [27] . Biochemical CRBN binding analysis confirmed that WL40 interacts with the E3 UbR CRBN using thalidomide and lenalidomide as positive controls (Fig. 1b) . As expected, the Rpn13 inhibitor RA190 alone did not show any binding to CRBN (Fig. 1b) . We then examined whether our bivalent molecule, WL40, can bind to Rpn13. We designed a novel biochemical AlphaScreen assay to measure compound binding to Rpn13 (Fig. 1c) . Since Rpn13 recognizes polyubiquitin (polyUb), the GST-tagged Rpn13 and biotinylated polyUb are immobilized on the acceptor and donor beads of the AlphaScreen assay (obtained from PerkinElmer). Upon excitation, the donor bead releases a singlet of oxygen, which reaches the acceptor bead and creates an emission. The binding of RA190 and WL40 interrupts this recognition event and eliminates the signal. Using RA190 as a positive control, we further confirmed that WL40 binds to Rpn13 and interrupts Rpn13's recognition of the biotinylated polyubiquitin tail. (Fig. 1d) . Thus, we confirmed that WL40 can bind both Rpn13 and CRBN complex.
We next examined whether WL40 decreases cellular Rpn13 levels in MM cells. MM.1S cells were treated with various concentrations of WL40 (200, 400, or 800 nM) for 4, 8, and 16 h; protein lysates were then analyzed for Rpn13 levels using immunoblot analysis. A marked decrease in Rpn13 levels was noted in WL40-treated cells in a timedependent manner (Fig. 1e, upper panel) . Decrease in Rpn13 levels was detectable as early as 8 h after WL40 treatment and maximally (95%) reduced at 16 h. Rpn13 protein level reduction was not observed with RA190 treatment (Fig. 1e, lower panel) . There was no change in The cereblon AlphaScreen assay to measure the displacement of biotinylated-pomalidomide probe (triplicate means ± SD). c Schematic cartoon for the novel AlphaScreen assay to measure the binding activity of inhibitor with RPN13 proteins. d The RPN13 AlphaScreen assay to measure the binding activity of inhibitor with RPN13 proteins (triplicate means ± SD). e MM.1S cells were treated with WL40 or RA190 at the indicated concentrations and time periods; protein lysates were subjected to immunoblot analysis using anti-Rpn13 or anti-tubulin Abs. f MM.1S cells were treated with DMSO control, WL40 (400 nM), or RA190 (500 nM) for 16 h; cells were then washed and stained with Rpn13 Ab conjugated with Alexa Fluor 647, followed by flow cytometry analysis. Isotype Ab conjugated to Alexa Fluor 647 was used as control for nonspecific binding. Data were quantified using FACS Diva (BD Biosciences, USA) and FlowJo (FlowJo LLC, USA). g MM.1S-CRBN-KO cells were treated with WL40 (400 nM) or RA190 (500 nM) for 16 h; protein lysates were subjected to immunoblot analysis using anti-Rpn13 or anti-β-actin Abs. Inset: protein lysates from MM.1S. WT control and MM.1S-CRBN-KO cells were subjected to immunoblot analysis using anti-CRBN or anti-β-actin Abs. h Immunoblot showing the levels of Ub-GFP accumulation in a GFPu-1 reporter cell line treated with indicated concentrations of WL40 and RA190 for 16 h. Blots shown are representative of three independent experiments. i HCT116-WT and HCT116-CRISPR Rpn13-KO cells were treated with WL40 or RA190 at the indicated concentrations for 48 h, followed by assessment of cell viability using the WST assay (mean ± SD; p < 0.001; n = 3). Inset: protein lysates from Rpn13-WT and KO cells were subjected to immunoblot analysis using anti-Rpn13 or β-actin Abs protein levels of tubulin, used as a loading control (Fig. 1e) . To further corroborate our findings, we treated MM.1S cells with WL40, and then analyzed intracellular alterations in Rpn13 using flow cytometry. In concert with our data obtained using immunoblot analysis, a significant reduction in Rpn13 expression was noted in WL40-versus DMSO-, or RA190-treated cells (Fig. 1f) .
To confirm that CRBN presence is a prerequisite for the function of WL40 in cells, we utilized CRBN-knockout (KO) MM.1S cells [27, 38] , and examined the effect of WL40 on Rpn13 degradation. As shown in Fig. 1g , no decrease in Rpn13 levels was observed in WL40-versus DMSO control-treated CRBN-KO cells. These data demonstrate that WL40 degrades Rpn13 in a CRBNdependent manner (Fig. 1g) . We next utilized a Green Fluorescent Protein (GFP)u-1 reporter cell line expressing Ub-tagged GFP, which is marked for constitutive degradation by the proteasome. GFPu-1 cells were treated with WL40, and GFP levels were then analyzed using immunoblotting. As shown in Fig. 1h , WL40 treatment increases GFP levels, indicating the blockade of proteasomemediated GFP degradation. Similar results were observed in RA190-treated cells. These findings provide evidence for the requirement of Rpn13 engagement by WL40 for its activity (Fig. 1I) . Thus, we have developed a novel degrader that can engage with both RPN13 and CRBN simultaneously and induce targeted protein degradation.
To eliminate the potential impact of WL40 on proteasome function, we assessed the effect of WL40 on proteasome activities. Examination of both cellular extracts from WL40-treated MM cells and purified recombinant 20S proteasome showed that WL40 does not inhibit 20S proteasomal activities (chymotrypsin-like, trypsin-like, or caspase-like activities) (Fig. 2a, b) . Pretreatment of MM.1S cells with the PI, MG132, blocked WL40-mediated Rpn13 degradation, suggesting that Rpn13 degradation occurs through the proteasome and that proteasome function is required for WL40-induced RPN13 degradation, consistent with other reports of targeted protein degradation (Fig. 2c) . Together, these biochemical and cellular findings demonstrate that WL40 binds to CRBN and Rpn13 within cells and promotes ubiquitination of Rpn13, followed by subsequent proteasomal degradation of Rpn13.
We next evaluated the effect of WL40 on additional MM cell lines, including p53-mutated RPMI-8226 cells or bortezomib-resistant ANBL6.BR cells. WL40 (400 nM) Fig. 2 WL40 blocks proteasome-mediated protein degradation without inhibiting proteasome proteolytic activities. a MM.1S cells were treated with DMSO control, bortezomib, or WL40 at indicated concentration for 3 h; protein lysates were analyzed for proteasome activities (CT-L, chymotrypsin-like; T-L, trypsin-like; C-L, caspaselike). The percentage of proteasome activity was normalized to DMSO control (mean ± SD; n = 3). b Recombinant 20S proteasome was incubated with DMSO, bortezomib, or WL40 for 30 min, followed by assessment of proteasome activities. Bar graph shows percent proteasome activity after normalization with DMSO control (mean ± SD; n = 3). c MM.1S cells were pretreated with MG132 (10 µM) for 1 h, followed by addition of WL40 (400 nM) for 8 h. As a positive control for WL40-induced Rpn13 degradation, cells were also treated with WL40 alone for 8 h. Total protein lysates were subjected to immunoblots for Rpn13 and α-tubulin. d RPMI-8226 cells were treated with WL40 (400 nM) for 16 h; protein lysates were subjected to immunoblot analysis using anti-Rpn13 or anti-β-actin Abs. e ANBL6.BR cells were treated with WL40 (400 nM) or RA190 (500 nM) for 16 h; protein lysates were subjected to immunoblot analysis using antiRpn13 or anti-β-actin Abs. f (Left panel) MM.1S cells were treated with DMSO control, bortezomib (5 nM), RA190 (300 nM), or WL40 (200 nM) for indicated time periods; protein lysates were subjected to immunoblot analysis using antipolyubiquitin or anti-β-actin Abs. f (Right panel) ANBL6.BR cells were treated with DMSO control or WL40 (1 µM) for 6 h; protein lysates were subjected to immunoblot analysis using antipolyubiquitin or anti-β-actin Abs treatment induced RPN13 degradation in both cell lines (Fig. 2d, e) . We also examined whether WL40 triggers the accumulation of polyubiquitinated (PolyUb) protein, a hallmark event during proteasome inhibition, in these cell lines [39, 40] MM.1S and ANBL6.BR cells were treated with WL40, followed by analysis of ubiquitinated protein using immunoblotting. A marked increase in PolyUb proteins was detected in WL40-versus DMSO-treated cells (Fig. 2f) . PolyUb increase was also observed in bortezomiband RA190-treated cells, albeit to a lesser extent than observed in WL40-exposed cells (Fig. 2f) . The finding that WL40 triggered a more rapid and higher molecular weight PolyUb versus bortezomib suggests a distinct mechanism of action for these agents. Indeed, bortezomib only targets the 20S proteasomal activities and therefore leads to aggregation of lower molecular weight PolyUb proteins; whereas WL40 blocks the 19S proteasome and prevents deubiquitination of substrates, thereby resulting in higher molecular weight PolyUb proteins. Taken together, these data demonstrate that WL40 blocks proteasome-mediated protein degradation upstream of the 20S proteasome and promotes RPN13 degradation selectively, without inhibiting proteasomal activities.
Anti-MM activity of WL40
In order to examine whether WL40-triggerred Rpn13 degradation affects the viability of MM cells, we utilized a panel of MM cell lines sensitive or resistant to conventional (dexamethasone, alkylating agents, anthracyclines) or novel (bortezomib) therapies, including lines representing cytogenetically distinct MM subtypes. WL40 is more cytotoxic than the parental Rpn13 inhibitor RA190 against dexamethasone-sensitive MM.1S and resistant MM.1R isogenic MM cell lines (Fig. 3a) , indicating potent anti-MM activity of WL40 versus RA190 due to its ability to degrade Rpn13. IC 50 values for both MM.1S and MM.1R cells correlate with the DC 50 for Rpn13. Importantly, WL40 overcomes bortezomib resistance, evidenced by similar IC 50 values for both bortezomib-sensitive (ANBL6.WT) and -resistant (ANBL6.BR) cells (Fig. 3a, table) . In addition, cytotoxic activity of WL40 was observed even against p53- Fig. 3 WL40 triggers anti-MM activity as well as overcomes bortezomib-resistance and cytoprotective activity of MM BM microenvironment. a MM.1S and MM.1R cells were treated with DMSO control, WL40, or RA190 at indicated concentrations for 48 h, followed by assessment for cell viability using the WST assay (p < 0.05 for both cell lines; n = 3). Table: ANBL6.WT, ANBL6.BR, RPMI-8226, or INA6 MM cell lines were treated with DMSO control of WL40 for 48 h, followed by assessment for cell viability. The IC 50 of WL40 for cell lines is shown. b Purified CD138
+ patient MM cells were treated with DMSO control or WL40 at indicated concentrations for 48 h, followed by assessment for cell viability using the CellTiterGlo assay (mean ± SD of triplicate cultures; p < 0.001). c Normal PBMCs from healthy donors were treated with DMSO control or WL40 at indicated concentrations for 48 h, and then analyzed for cell viability using the CellTiter-Glo assay (mean ± SD of quadruplicate cultures). d MM.1S cells were cultured with or without patient BMSCs in the presence or absence of WL40 for 48 h, and cell proliferation was measured by the WST assay (mean ± SD; n = 3; p < 0.0001). e MM.1S cells were cultured with or without patient plasmacytoid dendritic cells (pDCs) in the presence or absence of WL40 for 48 h, and cell proliferation was measured by the WST assay (mean ± SD; n = 3; p < 0.0001) mutated RPMI-8226 cells and MM growth factor IL-6-dependent INA6 MM cells (Fig. 3a, table) . These data suggest that WL40 can overcome p53 mutation, a high-risk feature conferring drug resistance in MM, and triggers MM cell death even in the presence of pro-growth and -survival factor IL-6.
To further evaluate the clinical potential of our novel degrader, we next examined the effect of WL40 in MM patient cells. We first analyzed primary tumor (CD138 + ) cells from newly diagnosed (patient #1) and MM refractory to bortezomib/lenalidomide (patients #2-4) (Fig. 3b) . Treatment with WL40 decreased viability of all CD138 + patient cells (IC 50 range: 95-170 nM) (Fig. 3b) . Importantly, WL40 at the IC 50 for MM cells does not affect viability of normal PBMCs (Fig. 3c) , suggesting a favorable therapeutic index. Adhesion of MM cells to BMSCs induces MMpromoting growth factors and protects against cytotoxic activity of anti-MM drugs [41, 42] . Moreover, BM accessory cells such as pDCs, can also trigger MM cell proliferation, survival, and drug resistance [32] . Therefore, we next assessed the effect of WL40 using our patient MMBMSCs or MM-pDCs in vitro coculture assays. Even in these cocultures with BMSCs or pDCs, WL40 induced a dose-dependent decrease in the viability of MM cells. (Fig. 3d, e ). These data demonstrate that WL40 retains its anti-MM activity in the tumor-protective MM-host BM microenvironment.
Rpn13 degradation-induced signal transduction
We next examined the downstream signaling triggered by WL40 during Rpn13 degradation. WL40 treatment induces an increase in early-(Annexin V + /PI − ) and late-stage (Annexin V + /PI + ) apoptosis, associated with proteolytic cleavage of Poly (ADP) ribose polymerase (PARP) by immunoblotting, as well as activation of caspase-3, caspase-7, caspase-8 and caspase-9, assessed in caspase enzymatic activity assays (Fig. 4a-c, respectively) . Additionally, treatment of MM.1S and ANBL6.BR cells with WL40 triggers a reduction in the levels of cell cycle regulatory proteins (cyclin-B1, CDC25C, and CDC2), indicating growth arrest in these cells (Fig. 4d) . Examination of the p53/p21 apoptotic signaling axis showed an earlier .BR) for 16 h; protein lysates were then subjected to immunoblotting using antibodies against PARP, caspase-3, caspase-7, caspase-8, caspase-9, or β-actin. FL, full length; CF, cleaved fragment. c MM.1S cells were treated with DMSO control or WL40 (200 nM) for 12 h, followed by measurement of caspase-3, caspase-8, or caspase-9 enzymatic activity (mean ± SD; n = 3; p < 0.0001). d MM.1S and ANBL6.BR cells were treated with DMSO control or WL40 (200 nM for MM.1S; 1 µM for ANBL6.BR) for 16 h; protein lysates were then subjected to immunoblotting using specific antibodies against cyclin-B1, CDC25C, CDC2, or β-actin. e ANBL6.BR cells were treated with DMSO control, WL40 (1 µM), or RA190 (1 µM) for indicated time periods; protein lysates were subjected to immunoblotting using specific antibodies against p53, p21, BIP, PERK, p-eIF2α, calnexin, LC3A/B, and β-actin. f MM.1S cells were treated with DMSO control, WL40 (200 nM), or RA190 (300 nM) for indicated time periods; protein lysates were subjected to immunoblotting using specific antibodies against p53, p21, BIP, PERK, peIF2α, calnexin, LC3A/B, and β-actin. Blots shown are representative of three independent experiments induction of this pathway in WL40-versus Rpn13 inhibitor RA190-treated ANBL6.BR cells (Fig. 4e) . Elevated endoplasmic reticulum (ER)-associated protein degradation (ERAD) signaling is a hallmark of MM, which confers enhanced sensitivity to PIs. Since WL40, like botezomib, triggers PolyUb accumulation (Fig. 2f) , we next examined whether it increases ER stress and triggers associated unfolded protein response (UPR) signaling. Indeed, we found a rapid and robust induction of UPR proteins (BIP, PERK, phosphorylated eIF2α, or a lectin protein calnexin) in WL40-treated ANBL6.BR and MM.1S cells (Fig. 4e, f, respectively) . Of note, Rpn13 inhibitor RA190 also triggered UPR signaling, but with delayed kinetics and to a lesser extent than Rpn13 degrader WL40. Prior studies have established that ER stress also induces an alternative lysosomal pathway (autophagy) for degradation of misfolded proteins [40] . Here, we found that WL40 induces PERK, a key component in autophagic signaling. To further confirm the activation of autophagy by WL40, we examined alterations in the autophagic molecule LC3/Atg8. During autophagy, LC3/Atg8 is processed and attached to the autophagosome membrane by conjugation with phosphatidylethanolamine. Immunoblot analysis showed a significant increase in LC3A/B in WL40-versus DMSO-treated ANBL6.BR or MM.1S cells (Fig. 4e, f, respectively) . As for UPR signaling in ANBL6.BR cells, a more pronounced LC3 activation was noted after WL40 than RA190 treatment. Overall, these findings show that WL40-induced apoptosis is associated with activation of the caspase-cascade, p53/p21 signaling, ER stress response signaling, and autophagy. Importantly, we show that degradation of Rpn13 triggers more pronounced biologic sequelae in MM cells than domain-specific Rpn13 inhibition.
In vivo anti-MM activity of WL40
To fully understand the therapeutic potential of the RPN13 degrader, we evaluated the in vivo efficacy of WL40 using our human plasmacytoma xenograft mouse model [3, 34] . This model has been useful in validating novel anti-MM therapies bortezomib, carfilzomib, ixazomib, lenalidomide, and pomalidomide, which have translated to clinical trials and FDA approval. Treatment of MM.1S-bearing mice with intraperitoneal (IP) injections of WL40 (14.7 μM/kg) inhibits MM growth and prolongs host survival (Fig. 5a ). Rpn13 inhibitor RA190 (26.8 μM/kg) also attenuates MM tumor progression and extends mice survival (Fig. 5a, b,  respectively) . Importantly, use of even half the equimolar dose of WL40 versus RA190 achieves similar extent of tumor growth inhibition and host survival. These findings suggest that Rpn13 degradation could be a more potent strategy in blocking tumor progression than Rpn13 inhibition. WL40 was well tolerated, with no significant weight loss in WL40-treated mice (data not shown). Analysis of b Kaplan-Meier plots shows survival of mice. c Lysates of tumors harvested from control-, WL40-and RA190-treated mice were subjected to immunoblot analysis using antipolyubiquitin, anticleaved-caspase-8, or anti-β-actin Abs. d Tumor sections from vehicle control-, and WL40-treated mice were stained with antipolyubiquitin, Ki67, caspase-3 (cleaved form), and CD31 Abs. Scale bar, 10 μm tumors harvested from treated mice showed that WL40 induced increased accumulation of PolyUb proteins relative to tumors from control mice (Fig. 5c, d ). WL40 decreases proliferation, induces apoptosis, and blocks angiogenesis in harvested tumors, as assessed by Ki67, cleaved caspase-3, and CD31 staining, respectively (Fig. 5d) . These data therefore show more potent in vivo anti-MM activity of WL40 versus RA190.
In summary, we here describe the development of a small-molecule degrader, WL40, targeting UbR Rpn13, and validate its specificity and functionality using both biochemical and genetic models. Importantly, our studies using both in vitro and in vivo preclinical models of MM show potent anti-MM activity of WL40. Novel findings include the following: (1) we demonstrate the development of the first covalent inhibitor-based heterobifunctional degrader molecule of Rpn13; (2) using both pharmacological assays and in vivo tumor efficacy models, we show that the Rpn13 degrader is cell permeable and triggers potent anti-MM activity, even in the presence of cytoprotective tumor BM microenvironment, overcomes bortezomib resistance, and is active even in the context of mutated-p53; (3) Rpn13 degradation is a more efficient inducer of MM cell death than Rpn13 inhibition, evidenced by a more rapid and robust induction of ER stress response/UPR-and p53/p21-apoptotic signaling by WL40 than RA190; (4) our MM xenograft model study showed that significant tumor growth inhibition can be achieved using half the equimolar dose of WL40 versus Rpn13 inhibitor RA190; and (5) our study strongly suggests that degradation of tumorpromoting proteins within the UPS using the degronimid strategy is a plausible therapeutic approach, especially in cancers with elevated ER stress/UPR signaling such as MM.
Finally, the anti-MM activity of the IMiD, lenalidomide, occurs via CRBN complex-mediated degradation of Ikaros proteins, IKZF1, and IKZF3 [38] . This finding supports the therapeutic potential of strategies to induce degradation of tumorigenic target proteins via chemically synthesized small-molecule degraders. Importantly, extensive preclinical research shows that degraders may: reduce the need to maintain high systemic inhibitor levels for target inhibition and efficacy in vivo; neutralize even high levels of target protein expression and function; as well as degrade substrates and thereby avoid resistance mechanisms such as gene mutation or copy number alterations. Overall, our present study provides the rationale for the development of UPS-based degrader therapies, and further indicates the potential clinical utility of novel therapeutics targeting UbR Rpn13 to improve patient outcome in MM.
